6-Mercaptopurine: An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia.Toxicology: The science concerned with the detection, chemical composition, and biological action of toxic substances or poisons and the treatment and prevention of toxic manifestations.Carcinogenicity Tests: Tests to experimentally measure the tumor-producing/cancer cell-producing potency of an agent by administering the agent (e.g., benzanthracenes) and observing the quantity of tumors or the cell transformation developed over a given period of time. The carcinogenicity value is usually measured as milligrams of agent administered per tumor developed. Though this test differs from the DNA-repair and bacterial microsome MUTAGENICITY TESTS, researchers often attempt to correlate the finding of carcinogenicity values and mutagenicity values.Mutagens: Chemical agents that increase the rate of genetic mutation by interfering with the function of nucleic acids. A clastogen is a specific mutagen that causes breaks in chromosomes.Carcinogens: Substances that increase the risk of NEOPLASMS in humans or animals. Both genotoxic chemicals, which affect DNA directly, and nongenotoxic chemicals, which induce neoplasms by other mechanism, are included.Drosophila: A genus of small, two-winged flies containing approximately 900 described species. These organisms are the most extensively studied of all genera from the standpoint of genetics and cytology.Oxymetholone: A synthetic hormone with anabolic and androgenic properties. It is used mainly in the treatment of anemias. According to the Fourth Annual Report on Carcinogens (NTP 85-002), this compound may reasonably be anticipated to be a carcinogen. (From Merck Index, 11th ed)Rats, Inbred F344National Institute of Environmental Health Sciences (U.S.): Component of the NATIONAL INSTITUTES OF HEALTH. It conducts and supports basic and applied research to reduce the burden of human illness and dysfunction from environmental causes by, defining how environmental exposures, genetic susceptibility, and age interact to affect an individual's health. It was established in 1969.Spain: Parliamentary democracy located between France on the northeast and Portugual on the west and bordered by the Atlantic Ocean and the Mediterranean Sea.Silver: Silver. An element with the atomic symbol Ag, atomic number 47, and atomic weight 107.87. It is a soft metal that is used medically in surgical instruments, dental prostheses, and alloys. Long-continued use of silver salts can lead to a form of poisoning known as ARGYRIA.Colloids: Two-phase systems in which one is uniformly dispersed in another as particles small enough so they cannot be filtered or will not settle out. The dispersing or continuous phase or medium envelops the particles of the discontinuous phase. All three states of matter can form colloids among each other.Nucleolus Organizer Region: The chromosome region which is active in nucleolus formation and which functions in the synthesis of ribosomal RNA.Famous PersonsSilver Compounds: Inorganic compounds that contain silver as an integral part of the molecule.Adsorption: The adhesion of gases, liquids, or dissolved solids onto a surface. It includes adsorptive phenomena of bacteria and viruses onto surfaces as well. ABSORPTION into the substance may follow but not necessarily.Thioguanine: An antineoplastic compound which also has antimetabolite action. The drug is used in the therapy of acute leukemia.Spectrum Analysis, Raman: Analysis of the intensity of Raman scattering of monochromatic light as a function of frequency of the scattered light.Editorial Policies: The guidelines and policy statements set forth by the editor(s) or editorial board of a publication.Carcinoma, Ehrlich Tumor: A transplantable, poorly differentiated malignant tumor which appeared originally as a spontaneous breast carcinoma in a mouse. It grows in both solid and ascitic forms.Phosphoribosyl Pyrophosphate: The key substance in the biosynthesis of histidine, tryptophan, and purine and pyrimidine nucleotides.Nucleotides: The monomeric units from which DNA or RNA polymers are constructed. They consist of a purine or pyrimidine base, a pentose sugar, and a phosphate group. (From King & Stansfield, A Dictionary of Genetics, 4th ed)Hypoxanthines: Purine bases related to hypoxanthine, an intermediate product of uric acid synthesis and a breakdown product of adenine catabolism.Ribose-Phosphate Pyrophosphokinase: An enzyme that catalyzes the formation of phosphoribosyl pyrophosphate from ATP and ribose-5-phosphate. EC 2.7.6.1.Thioinosine: Sulfhydryl analog of INOSINE that inhibits nucleoside transport across erythrocyte plasma membranes, and has immunosuppressive properties. It has been used similarly to MERCAPTOPURINE in the treatment of leukemia. (From Martindale, The Extra Pharmacopoeia, 30th ed, p503)Kinetics: The rate dynamics in chemical or physical systems.Anthranilate Phosphoribosyltransferase: An enzyme that catalyzes the formation of N-5'-phosphoribosylanthranilic acid from anthranilate and phosphoribosylpyrophosphate, the first step in tryptophan synthesis in E. coli. It exists in a complex with ANTHRANILATE SYNTHASE in bacteria. EC 2.4.2.18.Hypoxanthine Phosphoribosyltransferase: An enzyme that catalyzes the conversion of 5-phosphoribosyl-1-pyrophosphate and hypoxanthine, guanine, or 6-mercaptopurine to the corresponding 5'-mononucleotides and pyrophosphate. The enzyme is important in purine biosynthesis as well as central nervous system functions. Complete lack of enzyme activity is associated with the LESCH-NYHAN SYNDROME, while partial deficiency results in overproduction of uric acid. EC 2.4.2.8.Dissertations, Academic as Topic: Dissertations embodying results of original research and especially substantiating a specific view, e.g., substantial papers written by candidates for an academic degree under the individual direction of a professor or papers written by undergraduates desirous of achieving honors or distinction.Methylthioinosine: 6-(Methylthio)-9-beta-D-ribofuranosylpurine. An analog of inosine with a methylthio group replacing the hydroxyl group in the 6-position.Azathioprine: An immunosuppressive agent used in combination with cyclophosphamide and hydroxychloroquine in the treatment of rheumatoid arthritis. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), this substance has been listed as a known carcinogen. (Merck Index, 11th ed)Immunosuppressive Agents: Agents that suppress immune function by one of several mechanisms of action. Classical cytotoxic immunosuppressants act by inhibiting DNA synthesis. Others may act through activation of T-CELLS or by inhibiting the activation of HELPER CELLS. While immunosuppression has been brought about in the past primarily to prevent rejection of transplanted organs, new applications involving mediation of the effects of INTERLEUKINS and other CYTOKINES are emerging.Inflammatory Bowel Diseases: Chronic, non-specific inflammation of the GASTROINTESTINAL TRACT. Etiology may be genetic or environmental. This term includes CROHN DISEASE and ULCERATIVE COLITIS.Academic DissertationsCrohn Disease: A chronic transmural inflammation that may involve any part of the DIGESTIVE TRACT from MOUTH to ANUS, mostly found in the ILEUM, the CECUM, and the COLON. In Crohn disease, the inflammation, extending through the intestinal wall from the MUCOSA to the serosa, is characteristically asymmetric and segmental. Epithelioid GRANULOMAS may be seen in some patients.Colitis, Ulcerative: Inflammation of the COLON that is predominantly confined to the MUCOSA. Its major symptoms include DIARRHEA, rectal BLEEDING, the passage of MUCUS, and ABDOMINAL PAIN.Precursor Cell Lymphoblastic Leukemia-Lymphoma: A neoplasm characterized by abnormalities of the lymphoid cell precursors leading to excessive lymphoblasts in the marrow and other organs. It is the most common cancer in children and accounts for the vast majority of all childhood leukemias.Methyltransferases: A subclass of enzymes of the transferase class that catalyze the transfer of a methyl group from one compound to another. (Dorland, 28th ed) EC 2.1.1.Antimetabolites: Drugs that are chemically similar to naturally occurring metabolites, but differ enough to interfere with normal metabolic pathways. (From AMA Drug Evaluations Annual, 1994, p2033)Antimetabolites, Antineoplastic: Antimetabolites that are useful in cancer chemotherapy.Methotrexate: An antineoplastic antimetabolite with immunosuppressant properties. It is an inhibitor of TETRAHYDROFOLATE DEHYDROGENASE and prevents the formation of tetrahydrofolate, necessary for synthesis of thymidylate, an essential component of DNA.
(1/449) Regulation of de novo purine biosynthesis in human lymphoblasts. Coordinate control of proximal (rate-determining) steps and the inosinic acid branch point.

Purine nucleotide synthesis de novo has been studied in a permanent tissue culture line of human splenic lymphoblasts with particular attention to coordination of control of the proximal (rate-determining) steps with the distal branch point of the pathway. An assay was used which permits simultaneous determination of the overall rate of labeling of all intracellular purines with sodium [14C]formate, as well as the distribution of isotope into all intracellular guanine- and adenine-containing compounds. The guanine to adenine labeling ratio was used as an index of IMP branch point regulation. It was found that exogenous adenine and guanine produce feedback-controlling effects not only on the first step in the de novo pathway, but also on the IMP branch point. Concentrations of adenine which produce less than 40% inhibition of the overall rate of de novo purine synthesis do so by selectively inhibiting adenine nucleotide synthesis de novo by 50 to 70% while stimulating guanine nucleotide synthesis de novo by up to 20%. A reciprocal effect is seen with exogenous guanine. The adenosine analog 6-methylmercaptopurine ribonucleoside selectivity inhibits adenine nucleotide synthesis via the de novo pathway but not from exogenous hypoxanthine. Thus, the reactions of purine nucleotide interconversion, in particular adenylosuccinate synthetase, may be regulated differently in cells deriving their purine nucleotides solely from de novo synthesis than when deriving them via "salvage" of preformed hypoxanthine.  (+info)

(2/449) Therapeutic drug monitoring of antimetabolic cytotoxic drugs.

Therapeutic drug monitoring is not routinely used for cytotoxic agents. There are several reasons, but one major drawback is the lack of established therapeutic concentration ranges. Combination chemotherapy makes the establishment of therapeutic ranges for individual drugs difficult, the concentration-effect relationship for a single drug may not be the same as that when the drug is used in a drug combination. Pharmacokinetic optimization protocols for many classes of cytotoxic compounds exist in specialized centres, and some of these protocols are now part of large multicentre trials. Nonetheless, methotrexate is the only agent which is routinely monitored in most treatment centres. An additional factor, especially in antimetabolite therapy, is the existence of pharmacogenetic enzymes which play a major role in drug metabolism. Monitoring of therapy could include assay of phenotypic enzyme activities or genotype in addition to, or instead of, the more traditional measurement of parent drug or drug metabolites. The cytotoxic activities of mercaptopurine and fluorouracil are regulated by thiopurine methyltransferase (TPMT) and dihydropyrimidine dehydrogenase (DPD), respectively. Lack of TPMT functional activity produces life-threatening mercaptopurine myelotoxicity. Very low DPD activity reduces fluorouracil breakdown producing severe cytotoxicity. These pharmacogenetic enzymes can influence the bioavailability, pharmacokinetics, toxicity and efficacy of their substrate drugs.  (+info)

(3/449) Prognostic importance of 6-mercaptopurine dose intensity in acute lymphoblastic leukemia.

6-Mercaptopurine (6MP) and methotrexate are the backbone of continuation therapy for childhood acute lymphoblastic leukemia (ALL). In studies of oral 6MP and methotrexate, indices of chronic systemic exposure to active metabolites of these agents, namely, red blood cell (RBC) concentrations of methotrexate polyglutamates (MTXPGs) and thioguanine nucleotides (TGNs) have positively correlated with event-free survival (EFS). Our objective was to evaluate whether MTXPGs, TGNs, and the dose intensity of administered methotrexate and 6MP were prognostic in the setting of a treatment protocol in which all treatment was coordinated through a single center, and the weekly doses of methotrexate were given parenterally. On protocol Total XII, 182 children achieved remission and received weekly methotrexate 40 mg/m2 parenterally and daily oral 6MP, interrupted every 6 weeks during the first year by pulse chemotherapy. A total of 709 TGN, 418 MTX-PG, and 267 thiopurine methyltransferase (TPMT) measurements, along with complete dose intensity information (dose received divided by protocol dose per week) for 19,046 weeks of 6MP and methotrexate, were analyzed. In univariate analyses, only higher dose intensity of 6MP and of weekly methotrexate were significant predictors of overall EFS (P =.006 and. 039, respectively). The occurrence of neutropenia was associated with worse outcome (P =.040). In a multivariate analysis, only higher dose intensity of 6MP (P =.020) was a significant predictor of EFS, with lower TPMT activity (P =.096) tending to associate with better outcome. 6MP dose intensity was also associated (P =.007) with EFS among patients with homozygous wild-type TPMT phenotype. Lower 6MP dose intensity was primarily due to missed weeks of therapy and not to reductions in daily dose. We conclude that increased dose-intensity of oral 6MP is an important determinant of EFS in ALL, particularly among those children with a homozygous wild-type TPMT phenotype. However, increasing intensity of therapy such that neutropenia precludes chemotherapy administration may be counterproductive.  (+info)

(4/449) Purine analogue 6-methylmercaptopurine riboside inhibits early and late phases of the angiogenesis process.

Angiogenesis has been identified as an important target for antineoplastic therapy. The use of purine analogue antimetabolites in combination chemotherapy of solid tumors has been proposed. To assess the possibility that selected purine analogues may affect tumor neovascularization, 6-methylmercaptopurine riboside (6-MMPR), 6-methylmercaptopurine, 2-aminopurine, and adenosine were evaluated for the capacity to inhibit angiogenesis in vitro and in vivo. 6-MMPR inhibited fibroblast growth factor-2 (FGF2)-induced proliferation and delayed the repair of mechanically wounded monolayer in endothelial GM 7373 cell cultures. 6-MMPR also inhibited the formation of solid sprouts within fibrin gel by FGF2-treated murine brain microvascular endothelial cells and the formation of capillary-like structures on Matrigel by murine aortic endothelial cells transfected with FGF2 cDNA. 6-MMPR affected FGF2-induced intracellular signaling in murine aortic endothelial cells by inhibiting the phosphorylation of extracellular signal-regulated kinase-2. The other molecules were ineffective in all of the assays. In vivo, 6-MMPR inhibited vascularization in the chick embryo chorioallantoic membrane and prevented blood vessel formation induced by human endometrial adenocarcinoma specimens grafted onto the chorioallantoic membrane. Also, topical administration of 6-MMPR caused the regression of newly formed blood vessels in the rabbit cornea. Thus, 6-MMPR specifically inhibits both the early and the late phases of the angiogenesis process in vitro and exerts a potent anti-angiogenic activity in vivo. These results provide a new rationale for the use of selected purine analogues in combination therapy of solid cancer.  (+info)

(5/449) A randomized comparison of all transretinoic acid (ATRA) followed by chemotherapy and ATRA plus chemotherapy and the role of maintenance therapy in newly diagnosed acute promyelocytic leukemia. The European APL Group.

All transretinoic acid (ATRA) followed by daunorubicin (DNR)-AraC chemotherapy (CT) has improved the outcome of acute promyelocytic leukemia (APL) by comparison to CT alone. In a randomized trial, (1) we compared 2 induction schedules (ATRA followed by CT [ATRA-->CT] and ATRA plus CT [ATRA+CT, with CT added on day 3 of ATRA treatment]) and (2) we assessed the role of maintenance treatment. Four hundred thirteen patients CT and ATRA+CT (initially randomized patients); patients with a WBC count greater than (high WBC count group, n = 163) and patients 66 to 75 years of age with a WBC count greater than 5,000/microL (elderly group, n = 42) were not initially randomized and received ATRA+CT from day 1 and ATRA -->CT, respectively. All patients achieving CR received 2 additional DNR-AraC courses (only 1 in patients 66 to 75 years of age) and were then randomized for maintenance between no treatment, intermittent ATRA (15 days every 3 months) for 2 years, continuous low-dose CT (6 mercaptopurine + methotrexate) for 2 years, or both, using a 2-by-2 factorial design. Overall, 381 (92%) of the patients achieved complete remission (CR), 31 (7%) suffered an early death, and only 1 patient had leukemic resistance. ATRA syndrome occurred in 64 patients (15%) and was fatal in 5 cases. The CR rate was similar in all induction treatment groups. Event-free survival (EFS) was significantly lower in the high WBC group (P =.0002) and close to significance in the elderly group (P =.086) as compared with initially randomized patients. Relapse at 2 years was estimated at 6% in the ATRA+CT group, versus 16% in the ATRA-->CT group (P =.04, relative risk [RR] =.41). EFS at 2 years was estimated at 84% in the ATRA+CT group, versus 77% in the ATRA-->CT group (P =.1, RR =.62). Two hundred eighty-nine patients were randomized for maintenance. The 2-year relapse rate was 11% in patients randomized to continuous maintenance CT and 27% in patients randomized to no CT (P =.0002) and 13% in patients randomized to intermittent ATRA and 25% in patients randomized to no ATRA (P =.02). An additive effect of continuous maintenance CT and intermittent ATRA was seen, and only 6 of the 74 patients who received both maintenance treatments had relapsed. Overall survival was improved in patients who received maintenance CT (P =.01), and there was a trend for better survival in patients who received maintenance ATRA (P =.22). Our findings strongly suggest that early addition of chemotherapy to ATRA and maintenance therapy combining continuous CT and intermittent ATRA can reduce the incidence of relapse in APL. This effect already translates into significantly better survival for maintenance treatment with continuous CT.  (+info)

(6/449) Glutathione-dependent metabolism of cis-3-(9H-purin-6-ylthio)acrylic acid to yield the chemotherapeutic drug 6-mercaptopurine: evidence for two distinct mechanisms in rats.

cis-3-(9H-Purin-6-ylthio)acrylic acid (PTA) is a structural analog of azathioprine, a prodrug of the antitumor and immunosuppressive drug 6-mercaptopurine (6-MP). In this study, we examined the in vitro and in vivo metabolism of PTA in rats. Two metabolites of PTA, 6-MP and the major metabolite, S-(9H-purin-6-yl)glutathione (PG), were formed in a time- and GSH-dependent manner in vitro. Formation of 6-MP and PG occurred nonenzymatically, but 6-MP formation was enhanced 2- and 7-fold by the addition of liver and kidney homogenates, respectively. Purified rat liver glutathione S-transferases enhanced 6-MP formation from PTA by 1.8-fold, whereas human recombinant alpha, mu, and pi isozymes enhanced 6-MP formation by 1.7-, 1.3-, and 1.3-fold, respectively. In kidney homogenate incubations, PG accumulation was only observed during the first 15 min because of further metabolism by gamma-glutamyltranspeptidase, dipeptidase, and beta-lyase to yield 6-MP, as indicated by the use of the inhibitors acivicin and aminooxyacetic acid. Based on these results and other lines of evidence, two different GSH-dependent pathways are proposed for 6-MP formation: an indirect pathway involving PG formation and further metabolism to 6-MP, and a direct pathway in which PTA acts as a Michael acceptor. HPLC analyses of urine of rats treated i.p. with PTA (100 mg/kg) showed that 6-MP was formed in vivo and excreted in urine without apparent liver or kidney toxicity. Collectively, these studies show that PTA is metabolized to 6-MP both in vitro and in vivo and may therefore be a useful prodrug of 6-MP.  (+info)

(7/449) Modification of cardiac Na(+) current by RWJ 24517 and its enantiomers in guinea pig ventricular myocytes.

We examined the effects of the cardiotonic agent RWJ 24517 (Carsatrin, racemate) and its (S)- and (R)-enantiomers on action potential duration, Na(+) current (I(Na)), and delayed rectifier K(+) current (I(K)) of guinea pig ventricular myocytes. RWJ 24517 (0. 1 and 1 microM) prolongation of action potential duration could not be accounted for by suppression of either the rapid (I(Kr)) or slow (I(Ks),) component of I(K), although RWJ 24517 did reduce I(Kr) at concentrations of 1 microM. A more dramatic effect of RWJ 24517 (0.1-1 microM) and the (S)-enantiomer of RWJ 24517 (0.1-3 microM) was an increase in peak I(Na) and slowing of the rate of I(Na) decay, eliciting a large steady-state current. Neither RWJ 24517 nor the (S)-enantiomer affected the fast time constant for I(Na) decay, but both significantly increased the slow time constant, in addition to increasing the proportion of I(Na) decaying at the slow rate. Both agents elicited a use-dependent decrease of peak I(Na) (3-10 microM), which probably resulted from a slowing of both fast and slow rates of recovery from inactivation. In contrast, the (R)-enantiomer of RWJ 24517 did not induce a steady-state component I(Na) or increase peak I(Na) up to 10 microM, but it decreased peak I(Na) at 30 microM. The (R)-enantiomer displayed little use-dependent reduction of I(Na) during trains of repetitive pulses and had no effect on rates of inactivation or recovery from inactivation. These actions of the racemate and the (S)-stereoisomer to slow inactivation and to prolong both Na(+) influx and action potential duration may contribute to the positive inotropic actions of these agents because the resulting accumulation of intracellular Na(+) would increase intracellular Ca(2+) via Na(+)/Ca(2+) exchange.  (+info)

(8/449) Drug therapy against a transplantable guinea pig leukemia.

The effects of six clinically active drugs were tested against a ttansplantable leukemia in inbred strain 2 guinea pigs. Cytoxan and 6-mercaptopurine were found to elicit a therqeutic response against this leukemia based on complete tumor regression of the established tumor as well as a substantial increase in survival time. Animals dying in the untreated control and drug-treated groups revealed typical generalized lymphoblastic leukemia. However, only Cytoxan-treated animals that had relapsed exhibited central nervous system involvement originating from the arachnoid membrane. A tow-drug combination of Cytoxan and 1-(2-chloroethyl)-3(trans-4-methylcyclohexyl)-1-nitrosourea was found not only to prevent meningeal leukemia development but also to result in "curing" all animals from their leukemia. This observation was based on a complete clinical, hematological, and histopathological "remission" period up to 176 days. The administration of 1-(2-chloroethyl)-3-(trans-4-methylcyclohexyl)-1-nitrosourea alone was observed not only to control the systemic leukemia but also to prevent central nervous system involvement. No relapses occurred after the first "remission" period was achieved in the groups of animals that received 1-(2-chloroethyl)-3-(trans-4-methylcyclohexyl)-1-nitrosourea.  (+info)

*  GlaxoSmithKline
Among these, albendazole, amoxicillin, amoxicillin-clavulanate, allopurinol, mercaptopurine, mupriocin, pyrimethamine, ... such as mercaptopurine. In 1959 the Wellcome Foundation bought Cooper, McDougall & Robertson Inc to become more active in ... mercaptopurine, pyrimethamine and zidovudine. In 2012, GSK pleaded guilty to promotion of drugs for unapproved uses, failure to ... mercaptopurine and thioguanine for the treatment of leukemia, allopurinol for gout, pyrimethamine for malaria, and the ...
*  List of OMIM disorder codes
RAF1 Noonan syndrome 6; 613224; NRAS Noonan-like syndrome with loose anagen hair; 607721; SHOC2 Norrie disease; 310600; NDP ... 6; 612201; NPPA Atrial fibrillation, familial, 7; 612240; KCNA5 Atrial septal defect 4; 611363; TBX20 Atrial septal defect 5; ... CHD7 Kallmann syndrome 6; 612702; FGF8 Kanzaki disease; 609242; NAGA Karak syndrome; 610217; PLA2G6 Kenny-Caffey syndrome-1; ... 6; 611092; GRIK2 Mental retardation, FRA12A type; 136630; DIP2B Mental retardation, joint hypermobility and skin laxity, with ...
*  Azathioprine
A 2003 population-based study in Denmark showed that the use of azathioprine and related mercaptopurine resulted in a seven- ... Nørgård, B.; L. Pedersen; K. Fonager; S. Rasmussen; H. Sørensen (March 2003). "Azathioprine, mercaptopurine and birth outcome: ... mercaptopurine on the rat litter in utero". Journal of reproduction and fertility. 4 (3): 297-302. doi:10.1530/jrf.0.0040297. ... It works via 6-thioguanine to disrupt the making of RNA and DNA by cells. Azathioprine was first made in 1957. It is on the ...
*  Katarína Horáková
13 (6): 495-500. doi:10.1007/BF02874220. PMID 5753016. Horáková, K; Drobnica, L; Nemec, P; Antos, A; Kristián, P (1968). " ... 16 (6): 591-6. PMID 5369024. Horáková, K; Drobnica, L; Nemec, P; Uher, M (1970). "Cyttoxic and cancerostatic activity of ... 27 (6): 408-12. doi:10.7164/antibiotics.27.408. PMID 4851620. Horáková, K; Kalafut, F; Navarová, J; Paterson, AR (1974). " ... 30 (6): 517-25. PMID 7032713. Horáková, K.; Jantová, S.; Devínsky, F. (1985). "Examination of the relation between the ...
*  VAMP regimen
Vincristine, amethopterin, 6-mercaptopurine, and prednisone for leukemia. http://ndt.oxfordjournals.org/content/20/6/1251.full. ...
*  List of antineoplastic agents
6 (1): 75-81. doi:10.1517/17425250903393745. ISSN 1742-5255. PMID 19968576. Ghanem H, Kantarjian H, Ohanian M, Jabbour E (Apr ... "Azathioprine and 6-mercaptopurine for maintenance of remission in ulcerative colitis". The Cochrane Database of Systematic ...
*  Idiopathic pulmonary haemosiderosis
6-mercaptopurine as a long-term therapy may prevent pulmonary haemorrhage. A 2007 scientific letter. reports preliminary ... Luo XQ, Ke ZY, Huang LB, Guan XQ, Zhang XL, Zhu J, Zhang YC (Nov 2008). "Maintenance therapy with dose-adjusted 6- ... mercaptopurine in idiopathic pulmonary hemosiderosis". Pediatric Pulmonology. 43 (11): 1067-71. doi:10.1002/ppul.20894. PMID ... 133 (6): 609-11. doi:10.1001/archpedi.1979.02130060049010. PMID 375718. Gilman PA, Zinkham WH (1969). "Severe idiopathic ...
*  Management of Crohn's disease
Azathioprine and 6-MP may be useful for the following indications: Maintenance therapy with azathioprine or 6-mercaptopurine ... 347 (6): 417-29. doi:10.1056/NEJMra020831. PMID 12167685. Dejaco, C.; Harrer, M.; Waldhoer, T.; Miehsler, W.; Vogelsang, H.; ... 18 (6): 419; author reply 419. PMID 15230268. "Cannabis-based drugs could offer new hope for inflammatory bowel disease ... Azathioprine and 6-mercaptopurine (6-MP) are the most commonly used immunosuppressants for maintenance therapy of Crohn's ...
*  Allopurinol
However, no improvement in leukemia response was noted with mercaptopurine-allopurinol co-therapy, so that work turned to other ... Because allopurinol inhibits the breakdown (catabolism) of the thiopurine drug mercaptopurine, and it was later tested by Wayne ... 31 (6): 640-647. doi:10.1111/j.1365-2036.2009.04221.x. PMID 20015102. Ansari AR, Duley JA (March 2012). "Azathioprine co- ... Optimizing 6-mercaptopurine and azathioprine therapy in the management of inflammatory bowel disease. World J Gastroenterol. ...
*  Mayo Collaborative Services v. Prometheus Laboratories, Inc.
When the patents were filed, the metabolites of these drugs were known, most importantly, 6-thioguanine, but the "right" level ... 2000). "Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease". ... wherein the level of 6-thioguanine less than about 230 pmol per 8x108 red blood cells indicates a need to increase the amount ... administering a drug providing 6-thioguanine to a subject having said immune-mediated gastrointestinal disorder; and (b) ...
*  Tisopurine
OXIPURINOL AND 6-MERCAPTOPURINE". British Journal of Clinical Pharmacology. 1 (2): 119-127. doi:10.1111/j.1365-2125.1974. ...
*  Thiopurine methyltransferase
1997). "Molecular diagnosis of thiopurine S-methyltransferase deficiency: genetic basis for azathioprine and mercaptopurine ... Weinshilboum RM, Sladek SL (1980). "Mercaptopurine pharmacogenetics: Monogenic inheritance of erythrocyte thiopurine ... 14 (7): 395-6. doi:10.1097/01.fpc.0000114753.08559.e9. PMID 15226671. Coulthard SA, Matheson EC, Hall AG, Hogarth LA (2005). " ... 6 (4): 279-90. doi:10.1097/00008571-199608000-00001. PMID 8873214. Krynetski E, Evans WE (2003). "Drug methylation in cancer ...
*  Management of ulcerative colitis
With mercaptopurine present, cells are not able to make DNA, and cell division is inhibited. In administering mercaptopurine it ... Mercaptopurine is a cytostatic drug that is an antimetabolite. The mercaptopurine molecule mimics purine, which is necessary ... Mercaptopurine inhibits the production of white blood cells generally. Because this makes the body more susceptible to ... Frequent blood cell counts are also recommended during administration of mercaptopurine. The drug may be toxic to bone marrow, ...
*  Thiopurine
6-Mercaptopurine (6-MP) 6-Thioguanine (6-TG) Azathioprine (AZA) Sahasranaman S, Howard D, Roy S (August 2008). "Clinical ... doi:10.1007/s00228-008-0478-6. PMID 18506437. Supreme Court Decision. Mayo Collaborative Services v. Prometheus Laboratories, ...
*  Lemelson-MIT Prize
Gertrude Elion (Lemelson-MIT Lifetime Achievement Award) for the following inventions: 6-mercaptopurine (Purinethol), the first ...
*  Autoimmune pancreatitis
4 (8): 1010-6; quiz 934. doi:10.1016/j.cgh.2006.05.017. PMID 16843735. Khandelwal, Ashish; Shanbhogue, Alampady Krishna; ... Immunomodulators such as azathioprine, and 6-mercaptopurine have been shown to extend remission of autoimmune pancreatitis ... irregular mass was observed in 6 (46%) patients. Whereas EUS-FNA is sensitive and specific for the diagnosis of pancreatic ...
*  Purine analogue
Mercaptopurine Thiopurines such as thioguanine are used to treat acute leukemias and remissions in acute granulocytic leukemias ... Purine Mercaptopurine Thioguanine Fludarabine Purine antimetabolites are commonly used to treat cancer by interfering with DNA ... It is nonenzymatically cleaved to 6-mercaptopurine that acts as a purine analogue and an inhibitor of DNA synthesis. By ...
*  Leukemia
129 (6): 704-714. doi:10.1182/blood-2016-10-695973. PMID 28028030. Reference list is found at image description page in ... 31 (6): 234-41. doi:10.1542/pir.31-6-234. PMID 20516235. "SEER Stat Fact Sheets: Leukemia". National Cancer Institute. 2011. ... 86 (8): 243-6. PMID 14582219. "Novartis Oncology". Archived from the original on 5 November 2013. Patients with Chronic ... 98 (6): 1721-6. doi:10.1182/blood.V98.6.1721. PMID 11535503. "JMMLfoundation.org". JMMLfoundation.org. Archived from the ...
*  Pharmacogenetics
... mercaptopurine/azathioprine, gemcitabine/capecitabine/AraC and tamoxifen, respectively. The decision to use pharmacogenetic ... 348 (6): 538-49. doi:10.1056/NEJMra020526. PMID 12571262. Phillips KA, Veenstra DL, Oren E, Lee JK, Sadee W (November 2001). " ... One in 300 people have two variant alleles and lack TPMT activity; these people need only 6-10% of the standard dose of the ... 348 (6): 529-37. doi:10.1056/NEJMra020021. PMID 12571261. Pharmacogenomics: Medicine and the new genetics from the Human Genome ...
*  Tioguanine
On the other hand, some cases of IBD that are resistant to mercaptopurine (or its pro-drug azathioprine) may be responsive to ... Cancers that do not respond to treatment with mercaptopurine do not respond to thioguanine. ... The plasma half-life of thioguanine is short, due to the rapid uptake into liver and blood cells and conversion to 6-TGN. The ... 6-Thioguanine is a thio analogue of the naturally occurring purine base guanine. 6-thioguanine utilises the enzyme hypoxanthine ...
*  7+3 (chemotherapy)
The addition of 6-thioguanine gave rise to the DAT regimen, and the addition of 6-mercaptopurine gave rise to the DAM regimen. ...
*  Juvenile myelomonocytic leukemia
Some combinations of 6-mercaptopurine with other chemotherapy drugs have produced results such as decrease in organ size and ... 29 (3): 164-6. doi:10.1007/s12288-012-0164-9. PMC 3710560 . PMID 24426365. The JMML Foundation European Working Group of MDS ... The differential diagnosis list includes infectious diseases like Epstein-Barr virus, cytomegalovirus, human herpesvirus 6, ... 6 or more café-au-lait (flat, coffee-colored) spots on the skin 2 or more neurofibromas (pea-size bumps that are noncancerous ...
*  Xanthine oxidase
61 (1): 71-6. doi:10.1021/np970237h. PMID 9461655. Chang WS, Lee YJ, Lu FJ, Chiang HC (Nov-Dec 1993). "Inhibitory effects of ... 33 (6): 774-97. doi:10.1016/S0891-5849(02)00956-5. PMID 12208366. "KEGG record for EC 1.17.3.2". Genome.jp. Retrieved 23 ... 62 (6): 633-44. doi:10.1111/j.1365-2125.2006.02785.x. PMC 1885190 . PMID 21894646. Heunks LM, Viña J, van Herwaarden CL, ... 277 (6 Pt 2): R1697-704. PMID 10600916. Higgins P, Dawson J, Walters M (2009). "The potential for xanthine oxidase inhibition ...
*  Inflammatory bowel disease
72 (6): 1488-1494. ISSN 0002-9165. PMID 11101476. Jostins L, Ripke S, Weersma RK, Duerr RH, McGovern DP, Hui KY, et al. (Nov 1 ... ISBN 0-7817-7153-6. Feller M, Huwiler K, Schoepfer A, Shang A, Furrer H, Egger M (2010). "Long-term antibiotic treatment for ... Archived (PDF) from the original on April 6, 2008. Retrieved 2009-11-07. Broomé U, Bergquist A (February 2006). "Primary ... doi:10.1007/s10787-011-0104-6. PMID 22205271. "Amgen, MGH, Broad form IBD Therapeutics Initiative". News: Discovery & ...
*  Febuxostat
2005 Nov;6(11):1168-78. PMID 16312139 Bruce Japsen for the Chicago Tribune. August 17, 2006. FDA puts gout treatment on hold ... 30 (6): 594-608. doi:10.1592/phco.30.6.594. PMID 20500048. Commissioner, Office of the. "Safety Alerts for Human Medical ... Febuxostat is contraindicated with concomitant use of theophylline and chemotherapeutic agents, namely azathioprine and 6- ... mercaptopurine, because it could increase blood plasma concentrations of these drugs, and therefore their toxicity. Febuxostat ...
*  James F. Holland
The study examined the combined use of two chemotherapy drugs, methotrexate and mercaptopurine. The trial was still in progress ... The combination of methotrexate, mercaptopurine, vincristine and prednisone - together known as the POMP regimen - produced ... Retrieved November 6, 2015. Schilsky, Richard L.; McIntyre, O. Ross; Holland, James F.; Frei, Emil (June 1, 2006). "A concise ... Retrieved November 6, 2015. Fand Incollingo, Beth (June 2013). "On the frontier of cancer care: Holland helped pioneer ...
Inhibition of Pruine Phosphoribosyltransferases of Ehrlich Ascites-tumour Cells by 6-mercaptopurine. - Semantic Scholar  Inhibition of Pruine Phosphoribosyltransferases of Ehrlich Ascites-tumour Cells by 6-mercaptopurine. - Semantic Scholar
5. From the low values of K(i) for 6-mercaptopurine, and from published evidence that ascites-tumour cells require supplies of ... The results obtained with guanine were confirmed by a spectrophotometric assay which was also used to assay the conversion of 6 ... mercaptopurine and 5-phosphoribosyl pyrophosphate into 6-thioinosine 5'-phosphate in the presence of 6-mercaptopurine ... 3. 25 mum-6-Mercaptopurine did not inhibit adenine phosphoribosyltransferase. 6-Mercaptopurine is a competitive inhibitor of ...
more infohttps://www.semanticscholar.org/paper/Inhibition-of-Pruine-Phosphoribosyltransferases-of-Atkinson-Murray/ea993b8da57fe2e07d2b1b7cb2d33945ede512bb
6-Mercaptopurine monohydrate 6112761  6-Mercaptopurine monohydrate 6112761
Related: 6-MERCAPTOPURINE, CAS 50-44-2. Formula: C5-H4-N4-S.H2-O. Synonyms/Common Names. *6H-Purine-6-thione, 1,7-dihydro-, ... Citation: Russell, L.B. and Hunsicker, P.R. Study of the base analog 6-mercaptopurine in the mouse specific-locus test. ... Citation: Russell, L.B. and Hunsicker, P.R. Study of the base analog 6-mercaptopurine in the mouse specific-locus test. ...
more infohttps://ntp.niehs.nih.gov/testing/status/agents/ts-6112761.html
6-mercaptopurine/aziathoprine and trying to conceive - Ulcerative Colitis  6-mercaptopurine/aziathoprine and trying to conceive - Ulcerative Colitis
We have a beautiful 6 mo. old angel. She is healthy and doing fine. It took my wife and me one try too!. Age: 30 ...
more infohttps://www.healingwell.com/community/default.aspx?f=38&m=1152274
6-Mercaptopurine Metabolite Levels in Children With Inflammatory Bowel Disease  6-Mercaptopurine Metabolite Levels in Children With Inflammatory Bowel Disease
These data suggest that the target range of 6-TG levels previously described by others did not apply to 58% of the pediatric ... There was a trend for higher 6-TG levels among patients in remission than among those with active disease (217 vs. 173); ... However, serial measurements of 6-MP metabolite levels in 50 patients with active disease showed that increasing 6-TG levels ... The authors evaluated the relation between 6-MP metabolite levels and disease activity in children and adolescents with ...
more infohttps://insights.ovid.com/crossref?an=00005176-200110000-00006
Characterization of 6-mercaptopurine transport by the SLC43A3-encoded nucleobase transporter | Molecular Pharmacology  Characterization of 6-mercaptopurine transport by the SLC43A3-encoded nucleobase transporter | Molecular Pharmacology
14C]6-MP and [3H]adenine had Km values [plusmn]SD of 163 [plusmn]; 126 [mu]M and 37 [plusmn] 26 [mu]M, respectively, for this ... Characterization of 6-mercaptopurine transport by the SLC43A3-encoded nucleobase transporter. Nicholas Ruel, Khanh H Nguyen, ... Characterization of 6-mercaptopurine transport by the SLC43A3-encoded nucleobase transporter. Nicholas Ruel, Khanh H Nguyen, ... Characterization of 6-mercaptopurine transport by the SLC43A3-encoded nucleobase transporter. Nicholas Ruel, Khanh H Nguyen, ...
more infohttp://molpharm.aspetjournals.org/content/early/2019/03/25/mol.118.114389
Synthesis, Anti-cancer Activity and Mechanism Study of 6-Mercapto-purine Derivatives | BenthamScience  Synthesis, Anti-cancer Activity and Mechanism Study of 6-Mercapto-purine Derivatives | BenthamScience
Synthesis, Anti-cancer Activity and Mechanism Study of 6-Mercapto-purine Derivatives. Author(s): Yu-qin Ma, Xing Yan, Rong Du, ... The novel 6-MP derivative discovered in this study is a promising drug candidate to be used as an anti-cancer agent. ... The novel 6-MP derivative discovered in this study is a promising drug candidate to be used as an anti-cancer agent. ... 6-mercaptopurine (6-MP) is the first active metabolite inhibitor shown to suppress cancer cells. The aim of this study is to ...
more infohttp://www.eurekaselect.com/134198
The impact of high-dose methotrexate on intracellular 6-mercaptopurine disposition during interval therapy of childhood acute...  The impact of high-dose methotrexate on intracellular 6-mercaptopurine disposition during interval therapy of childhood acute...
... and may enhance the activation of 6-mercaptopurine (6-MP) to 6-thioguanine nucleotides... ... Methotrexate Methotrexate polyglutamates Mercaptopurine Leukemia Thioguanine nucleotides This is a preview of subscription ... Rostami-Hodjegan A, Lennard L, Lilleyman JS (1995) The accumulation of mercaptopurine metabolites in age fractionated red blood ... Lennard L, Lilleman JS (1989) Variable mercaptopurine metabolism and treatment outcome in childhood lymphoblastic leukemia. J ...
more infohttps://link.springer.com/article/10.1007%2Fs00280-009-1205-4
The Influence of Azaserine and 6-Mercaptopurine on the in Vivo Metabolism of Ascites Tumor Cells | Cancer Research  The Influence of Azaserine and 6-Mercaptopurine on the in Vivo Metabolism of Ascites Tumor Cells | Cancer Research
The Influence of Azaserine and 6-Mercaptopurine on the in Vivo Metabolism of Ascites Tumor Cells. J. F. Fernandes, G. A. LePage ... The Influence of Azaserine and 6-Mercaptopurine on the in Vivo Metabolism of Ascites Tumor Cells ... The Influence of Azaserine and 6-Mercaptopurine on the in Vivo Metabolism of Ascites Tumor Cells ... The Influence of Azaserine and 6-Mercaptopurine on the in Vivo Metabolism of Ascites Tumor Cells ...
more infohttp://cancerres.aacrjournals.org/content/16/2/154
PLOS ONE: On the Action of Methotrexate and 6-Mercaptopurine on M. avium Subspecies paratuberculosis  PLOS ONE: On the Action of Methotrexate and 6-Mercaptopurine on M. avium Subspecies paratuberculosis
We hypothesized that the clinical efficacy of methotrexate and 6-MP in IBD may be to simply inhibit the growth of MAP. ... Methodology The effect on MAP growth kinetics by methotrexate and 6-MP were evaluated in cell culture of two strains each of ... This has been presumed to indicate the mechanism of action of methotrexate and 6-MP. Although controversial, there are ... treated with methotrexate and 6-mercaptopurine (6-MP) is associated with a decrease in pro-inflammatory cytokines. ...
more infohttps://journals.plos.org/plosone/article/authors?id=10.1371/journal.pone.0000161
COMPARATIVE STUDY OF 6-CHLOROPURINE AND 6-MERCAPTOPURINE IN ACUTE LEUKEMIA IN ADULTS* | Annals of Internal Medicine | American...  COMPARATIVE STUDY OF 6-CHLOROPURINE AND 6-MERCAPTOPURINE IN ACUTE LEUKEMIA IN ADULTS* | Annals of Internal Medicine | American...
Molecular Diagnosis of Thiopurine S-Methyltransferase Deficiency: Genetic Basis for Azathioprine and Mercaptopurine Intolerance ... Azathioprine and 6-Mercaptopurine in Crohn Disease: A Meta-Analysis Annals of Internal Medicine; 123 (2): 132-142 ... COMPARATIVE STUDY OF 6-CHLOROPURINE AND 6-MERCAPTOPURINE IN ACUTE LEUKEMIA IN ADULTS1 ROSE RUTH ELLISON; RICHARD T. SILVER; ... COMPARATIVE STUDY OF 6-CHLOROPURINE AND 6-MERCAPTOPURINE IN ACUTE LEUKEMIA IN ADULTS1. Ann Intern Med. ;51:322-338. doi: ...
more infohttp://annals.org/aim/article-abstract/677257/comparative-study-6-chloropurine-6-mercaptopurine-acute-leukemia-adults
Chromosome Damage and Polyploidization Induced in Human Peripheral Leukocytes in Vivo and in Vitro with Nitrogen Mustard, 6...  Chromosome Damage and Polyploidization Induced in Human Peripheral Leukocytes in Vivo and in Vitro with Nitrogen Mustard, 6...
Chromosome Damage and Polyploidization Induced in Human Peripheral Leukocytes in Vivo and in Vitro with Nitrogen Mustard, 6- ... Mercaptopurine, and A-649. Carlos E. Nasjleti and Herbert H. Spencer. Carlos E. Nasjleti ... Chromosome Damage and Polyploidization Induced in Human Peripheral Leukocytes in Vivo and in Vitro with Nitrogen Mustard, 6- ... Chromosome Damage and Polyploidization Induced in Human Peripheral Leukocytes in Vivo and in Vitro with Nitrogen Mustard, 6- ...
more infohttp://cancerres.aacrjournals.org/content/26/12_Part_1/2437
Azathioprine | 6-mercaptopurine | MotherToBaby  Azathioprine | 6-mercaptopurine | MotherToBaby
Azathioprine , 6-mercaptopurine Sunday, 01 January 2017. In every pregnancy, a woman starts out with a 3-5% chance of having a ... However, azathioprine and 6-MP leave the body quickly. These medicines should be gone from the body by the next day after your ... Azathioprine and 6-MP are medicines that decrease the activity of your body's immune system. These medicines are closely ... Can I take azathioprine or 6-MP while breastfeeding?. Yes. Only small amounts of azathioprine/6-MP have been found to enter ...
more infohttps://mothertobaby.org/fact-sheets/azathioprine-6mp/
Myelotoxicity after high-dose methotrexate in childhood acute leukemia is influenced by 6-mercaptopurine dosing but not by...  Myelotoxicity after high-dose methotrexate in childhood acute leukemia is influenced by 6-mercaptopurine dosing but not by...
Through enhancement of 6-mercaptopurine (6MP) bioavailability and inhibition of purine de novo synthesis, high-dose ... Through enhancement of 6-mercaptopurine (6MP) bioavailability and inhibition of purine de novo synthesis, high-dose ... Myelotoxicity after high-dose methotrexate in childhood acute leukemia is influenced by 6-mercaptopurine dosing but not by ... article{f7fbc0ab-6df0-4cfc-80dc-410252f423b0, abstract = {Through enhancement of 6-mercaptopurine (6MP) bioavailability and ...
more infohttps://lup.lub.lu.se/search/publication/5085132
A Phase II Study of Blinatumomab (NSC-765986) and POMP (Prednisone, Vincristine, Methotrexate, 6 Mercaptopurine) for Patients |...  A Phase II Study of Blinatumomab (NSC-765986) and POMP (Prednisone, Vincristine, Methotrexate, 6 Mercaptopurine) for Patients |...
Drugs used in chemotherapy, such as prednisone, vincristine sulfate, methotrexate, and mercaptopurine, work in different ways ... A Phase II Study of Blinatumomab (NSC-765986) and POMP (Prednisone, Vincristine, Methotrexate, 6 Mercaptopurine) for Patients ...
more infohttps://www.roswellpark.org/clinical-trials/list/2942
Adsorption of 6-Mercaptopurine and 6-Mercaptopurine-Riboside on Silver Colloid: A pH Dependent Surface Enhanced Raman...  Adsorption of 6-Mercaptopurine and 6-Mercaptopurine-Riboside on Silver Colloid: A pH Dependent Surface Enhanced Raman...
Part I. 6-Mercaptopurine. Domenii publicaţii > Fizica + Tipuri publicaţii > Articol în revistã ştiinţificã ... Adsorption of 6-Mercaptopurine and 6-Mercaptopurine-Riboside on Silver Colloid: A pH Dependent Surface Enhanced Raman ... Adsorption of 6-Mercaptopurine and 6-Mercaptopurine-Riboside on Silver Colloid: A pH Dependent Surface Enhanced Raman ...
more infohttp://ad-astra.ro/2007/02/01/adsorption-of-6-mercaptopurine-and-6-mercaptopurine-riboside-on-silver-colloid-a-ph-dependent-surface-enhanced-raman-spectroscopy-and-density-functional-theory-study-part-i-6-mercaptopurine/
Simultaneous determination of 6-thioguanine and methyl 6-mercaptopurine nucleotides of azathioprine in red blood cells by HPLC....  Simultaneous determination of 6-thioguanine and methyl 6-mercaptopurine nucleotides of azathioprine in red blood cells by HPLC....
6-thioguanine (6-TGN) and methyl 6-mercaptopurine nucleotides (Me6-MPNs) are the two major metabolites found in erythrocytes ... With this procedure, mean recoveries of 73.1% and 84.0% for 6-TGN and Me6-MPN derivatives, respectively, were found. ... we have developed a HPLC method for the simultaneous determination of 6-TGNs and Me6-MPNs in erythrocytes. A simple and rapid ... Kinetics of mercaptopurine and thioguanine nucleotides in renal transplant recipients during azathioprine treatment.. Stein ...
more infohttps://www.semanticscholar.org/paper/Simultaneous-determination-of-6-thioguanine-and-of-Dervieux-Boulieu/c0e2ecb3a29e007a2188bfb1949276e98cd12235
Browsing Electronic Theses and Dissertations by Subject 6-mercaptopurine  Browsing Electronic Theses and Dissertations by Subject "6-mercaptopurine"
Azathioprine and 6-mercaptopurine (AZA/6MP) are effective immunosuppressives commonly used for the treatment of inflammatory ... Browsing Electronic Theses and Dissertations by Subject "6-mercaptopurine". 0-9. A. B. C. D. E. F. G. H. I. J. K. L. M. N. O. P ... bowel disease (IBD). The mercaptopurine metabolites, 6-thioguanine (6TG) and 6-methylmercaptopurine ... ...
more infohttps://utmb-ir.tdl.org/utmb-ir/handle/2152.3/1/browse?value=6-mercaptopurine&type=subject
Optimal predictor for 6-mercaptopurine intolerance in Chinese children with acute lymphoblastic leukemia: NUDT15, TPMT, or ITPA...  Optimal predictor for 6-mercaptopurine intolerance in Chinese children with acute lymphoblastic leukemia: NUDT15, TPMT, or ITPA...
However, 6-MP also has dose-limiting toxicities, particularly life-threatening myelosuppression, due to genetic polymorphisms ... Here, we evaluated the associations of NUDT15, TPMT and ITPA genotypes with 6-MP intolerance in our cohort of childhood ALL ... 6-mercaptopurine (6-MP) contributes substantially to remarkable improvement in the survival of childhood acute lymphoblastic ... We identified the NUDT15 coding variant rs116855232 (c.415C , T), a newly discovered 6-MP toxicity-related locus in Asians, and ...
more infohttps://bmccancer.biomedcentral.com/articles/10.1186/s12885-018-4398-2
ChemIDplus - 20146-85-4 - IPPVHUKVALEWCZ-UHFFFAOYSA-L - Platinum-6-mercaptopurine - Similar structures search, synonyms,...  ChemIDplus - 20146-85-4 - IPPVHUKVALEWCZ-UHFFFAOYSA-L - Platinum-6-mercaptopurine - Similar structures search, synonyms,...
Platinum-6-mercaptopurine - Similar structures search, synonyms, formulas, resource links, and other chemical information. ... 1S/2C5H4N4S.Pt/c2*10-5-3-4(7-1-6-3)8-2-9-5;/h2*1-2H,(H2,6,7,8,9,10);/q;;+4/p-2. Download. ... Substance Name: Platinum-6-mercaptopurine. RN: 20146-85-4. InChIKey: IPPVHUKVALEWCZ-UHFFFAOYSA-L. ...
more infohttps://chem.nlm.nih.gov/chemidplus/rn/20146-85-4
2487-40-3 - 2-Thioxanthine, 98+% - 6-Hydroxy-2-mercaptopurine - 6-Hydroxy-2-purinethiol - B21606 - Alfa Aesar  2487-40-3 - 2-Thioxanthine, 98+% - 6-Hydroxy-2-mercaptopurine - 6-Hydroxy-2-purinethiol - B21606 - Alfa Aesar
Precautionary Statements: P261-P280a-P305+P351+P338-P304+P340-P405-P501a Avoid breathing dust/fume/gas/mist/vapours/spray. Wear protective gloves and eye/face protection. IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing. IF INHALED: Remove to fresh air and keep at rest in a position comfortable for breathing. Store locked up. Dispose of contents/container in accordance with local/regional/national/international regulations. ...
more infohttps://www.alfa.com/en/catalog/B21606/
A phase II clinical trial of 6-mercaptopurine (6MP) and methotrexate in patients with BRCA defective tumours: a study protocol....  A phase II clinical trial of 6-mercaptopurine (6MP) and methotrexate in patients with BRCA defective tumours: a study protocol....
... with BRCA mutated cancers.This multi-centre phase II single arm trial was designed to investigate the activity and safety of 6- ... mercaptopurine (6MP) 55 mg/m² per day, and methotrexate 15 mg/m² per week in patients with advanced breast or ovarian cancer, ... A phase II clinical trial of 6-mercaptopurine (6MP) and methotrexate in patients with BRCA defective tumours: a study protocol. ... A phase II clinical trial of 6-mercaptopurine (6MP) and methotrexate in patients with BRCA defective tumours: a study protocol. ...
more infohttps://www.ndorms.ox.ac.uk/publications/503518
Individualized toxicity-titrated 6-mercaptopurine increments during high-dose methotrexate consolidation treatment of lower...  Individualized toxicity-titrated 6-mercaptopurine increments during high-dose methotrexate consolidation treatment of lower...
Individualized toxicity-titrated 6-mercaptopurine increments during high-dose methotrexate consolidation treatment of lower ... 6-Mercaptopurine; Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Dose-Response ... This study explored the feasibility and toxicity of individualized toxicity-titrated 6-mercaptopurine (6MP) dose increments ...
more infohttp://www.forskningsdatabasen.dk/en/catalog/187824428
Gentaur Molecular :BioBasic \ 6 Mercaptopurine \ M714163  Gentaur Molecular :BioBasic \ 6 Mercaptopurine \ M714163
Mercaptopurine \ M714163 for more molecular products just contact us ... Pax6 Pax-6 Sey] Paired box protein Pax-6 (Oculorhombin). [CDK6 CDKN6] Cyclin-dependent kinase 6 (EC 2.7.11.22) (Cell division ... Pax6 Pax-6 Sey] Paired box protein Pax-6 (Oculorhombin). [GAS6 AXLLG] Growth arrest-specific protein 6 (GAS-6) (AXL receptor ... Il6 Il-6] Interleukin-6 (IL-6) (B-cell hybridoma growth factor) (Interleukin HP-1). [FAS APT1 FAS1 TNFRSF6] Tumor necrosis ...
more infohttp://www.antibody-antibodies.com/product162944-BioBasic-6_Mercaptopurine.html
Purixan® // About Purixan® 6-mercaptopurine - oral suspension liquid - FDA Approved mercaptopurine, Purixan - alternative 6-MP...  Purixan® // About Purixan® 6-mercaptopurine - oral suspension liquid - FDA Approved mercaptopurine, Purixan - alternative 6-MP...
... an FDA-Approved oral suspension form of mercaptopurine, Purixan offers flexible, accurate dosing, consistent absorption - an ... alternative to current mercaptopurine therapies for patients with Acute Lymphoblastic Leukemia ... The efficacy of mercaptopurine in keeping children and adults with ALL disease free has been established by a number of ... PURIXAN (mercaptopurine) is indicated for the treatment of patients with acute lymphoblastic leukemia as part of a combination ...
more infohttp://www.purixan-us.com/about/
Krames Online - Mercaptopurine, 6-MP tablets  Krames Online - Mercaptopurine, 6-MP tablets
Mercaptopurine, 6-MP tablets. What is this medicine?. MERCAPTOPURINE, 6-MP (mer kap toe PYOOR een) is a chemotherapy drug. It ... an unusual or allergic reaction to mercaptopurine, other medicines, foods, dyes, or preservatives ...
more infohttp://princetonhcs.kramesonline.com/Medications/121,574
  • The bioavailability of PURIXAN is equivalent to that of the tablet form of mercaptopurine, as measured by the AUC (area under the concentration curve). (purixan-us.com)
  • It was concluded that the Trivedi Effect ® -Consciousness Energy Healing Treatment might have generated a new polymorphic form of 6-mercaptopurine which would offer better solubility, absorption, and bioavailability compared with the control sample. (diagrid.org)
  • In the current study, 58% of patients in remission had 6-TG levels less than 235. (ovid.com)
  • However, serial measurements of 6-MP metabolite levels in 50 patients with active disease showed that increasing 6-TG levels correlated significantly with disease remission in patients followed up longitudinally (P = 0.04). (ovid.com)
  • These data suggest that the target range of 6-TG levels previously described by others did not apply to 58% of the pediatric patients with IBD in remission. (ovid.com)
  • 7. Timmer A, Patton PH, Chande N, McDonald JWD, MacDonald JK (2016) Azathioprine and 6-mercaptopurine for maintenance of remission in ulcerative colitis. (diagrid.org)
  • A Cochrane systematic review that included 13 randomized controlled trials, concluded that azathioprine and 6-mercaptopurine are not effective for inducing remission when a person has Crohn's Disease. (wikipedia.org)
  • NUDT15 variant is an optimal predictor for 6-MP intolerance in Chinese pediatric ALL patients and may have greatly clinical implications for individualized therapy. (biomedcentral.com)
  • 6. WHO (2015) WHO Model List of Essential Medicines, 19th List, World Health Organization. (diagrid.org)
  • The efficacy of mercaptopurine in keeping children and adults with ALL disease free has been established by a number of national and international trials. (purixan-us.com)
  • Furthermore, transfection of HEK293 cells with SLC43A3 increased the sensitivity of the cells to the cytotoxic effects of 6-MP by more than 7-fold. (aspetjournals.org)
  • Associations between genotypes and 6-MP dose sensitivity, leukopenia, hepatotoxicity, and therapy interruption were evaluated. (biomedcentral.com)
  • Chromosomal analysis of peripheral leukocytes in patients being treated with nitrogen mustard, 6-mercaptopurine, and A-649 demonstrated an increase in polyploidy, including cells showing endoreduplication. (aacrjournals.org)
  • Patients with NUDT15 homogenous genotype (TT) were highly sensitive to 6-MP (dose intensity of 60.27%) compared to these with heterozygous genotype (TC) or wild type (CC), who tolerated an average dose intensity of 83.83 and 94.24%, respectively. (biomedcentral.com)
  • PURIXAN offers patients and healthcare professionals a liquid formulation as an alternative to the mercaptopurine tablet. (purixan-us.com)
  • Folic acid might also be counter-productive for patients taking 6-MP and related drugs that inhibit all cell division. (wikipedia.org)
  • 1. Maese L, Raetz, E (2018) Simplifying 6-MP Delivery. (diagrid.org)
  • 6-Mercaptopurine (6-MP) is a drug with demonstrated cell-type specific effects on vascular cells both in vitro and in vivo, inhibiting proliferation of SMCs while promoting survival of endothelial cells. (biomedcentral.com)
  • Nur77 has various protective functions in vascular cells both in vitro and in vivo, and exerts its beneficial effects in a cell-type specific fashion [ 6 ]. (biomedcentral.com)
  • The aim of this study is to investigate the bioactivity of 6-MP derivatives and discover new anti-cancer agents. (eurekaselect.com)
  • Four 6-mercaptopurine (6-MP) derivatives were synthesized and their anti-cancer activities were analyzed. (eurekaselect.com)
  • Among the synthesized derivatives, 6-((naphthalen-2-ylmethyl)thio)-9H-purine (NMSP) which possessing a β-naphthalene, showed better anti-cancer activity than other compounds, with an IC 50 value 6.09µg/mL. (eurekaselect.com)
  • Promising biomarkers for predicting 6-MP-induced leukopenia is still unclear in Chinese population. (biomedcentral.com)
  • However, 6-MP also has dose-limiting toxicities, particularly life-threatening myelosuppression, due to genetic polymorphisms in enzymes that metabolize 6-MP. (biomedcentral.com)
  • PURIXAN reduced the variability in the absorption of mercaptopurine, proving itself to be a dependable and reliable alternative to the tablet. (purixan-us.com)
  • The novel 6-MP derivative discovered in this study is a promising drug candidate to be used as an anti-cancer agent. (eurekaselect.com)
  • The aim of the present study was to investigate whether 6-MP-eluting stents are similarly effective in preventing stenosis in porcine coronary arteries after 3 months, in order to assess the eligibility for human application. (biomedcentral.com)
  • The latent heat of evaporation and latent heat of fusion of the treated 6-mercaptopurine were significantly increased by 11.81% and 14.97% compared with the control sample. (diagrid.org)
  • In conclusion, although 6-MP was previously found to potently inhibit SMC proliferation, reduce inflammation and promote endothelial cell survival, thereby effectively reducing in-stent restenosis in rabbits, stents containing 300 μg 6-MP did not reduce stenosis and inflammation in porcine coronary arteries. (biomedcentral.com)